Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
NCT ID: NCT03959345
Last Updated: 2022-04-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE4
Total Enrollment
215 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-31
Study Completion Date
2022-02-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin. Previous studies using different therapies and combination treatment fall to improve survival in these patients.
Aim: to demonstrate the efficacy of the cloxacillin and fosfomycin combination administered during the first week of treatment, compared with cloxacillin monotherapy in patients with MSSA bacteremia in treatment success. Methods: A multicentre, superiority, open-label, randomized, phase IV-III, two-armed parallel (1:1) groups clinical trial. Adult patients with MSSA bacteremia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment, or Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
The primary endpoint is the treatment success measured at day 7 of treatment; a composite endpoint defined by all of the following criteria met after randomization: patient alive at day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever resolved at day 7 AND negative blood cultures for S. aureus at day 7.
In case of achieving statistical differences in the primary endpoint, investigators will perform a hierarchical analysis of the treatment success at Test of Cure visit (TOC, 12 weeks after randomization), defined by the presence of all of the following: patient alive at TOC AND no evidence of microbiological treatment failure defined as isolation of S. aureus from blood culture or other sterile site from day 8 after randomization until TOC.
Investigators have assumed a 74% of treatment success in monotherapy group. Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 183 subjects are necessary in first group and 183 in the second to find a statistically significant difference of 12%. It has been anticipated a drop-out rate of 5%.
Discussion: Randomized studies assessing efficacy of different treatment in MSSA bacteremia are lacking. This study could help to improve knowledge about MSSA bacteremia and whether combined treatment with cloxacillin and fosfomycin could improve outcomes compared with standard treatment.
Aim: to demonstrate the efficacy of the cloxacillin and fosfomycin combination administered during the first week of treatment, compared with cloxacillin monotherapy in patients with MSSA bacteremia in treatment success. Methods: A multicentre, superiority, open-label, randomized, phase IV-III, two-armed parallel (1:1) groups clinical trial. Adult patients with MSSA bacteremia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment, or Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
The primary endpoint is the treatment success measured at day 7 of treatment; a composite endpoint defined by all of the following criteria met after randomization: patient alive at day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever resolved at day 7 AND negative blood cultures for S. aureus at day 7.
In case of achieving statistical differences in the primary endpoint, investigators will perform a hierarchical analysis of the treatment success at Test of Cure visit (TOC, 12 weeks after randomization), defined by the presence of all of the following: patient alive at TOC AND no evidence of microbiological treatment failure defined as isolation of S. aureus from blood culture or other sterile site from day 8 after randomization until TOC.
Investigators have assumed a 74% of treatment success in monotherapy group. Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 183 subjects are necessary in first group and 183 in the second to find a statistically significant difference of 12%. It has been anticipated a drop-out rate of 5%.
Discussion: Randomized studies assessing efficacy of different treatment in MSSA bacteremia are lacking. This study could help to improve knowledge about MSSA bacteremia and whether combined treatment with cloxacillin and fosfomycin could improve outcomes compared with standard treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
NCT01898338
Staph Aureus Methicillin Resistant Bacteremia
COMPLETED
PHASE3
Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia
NCT06695832
Staphylococcus Aureus Bacteremia
ACTIVE_NOT_RECRUITING
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
NCT03162250
Bacteremia
COMPLETED
PHASE1
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
NCT05184764
Bacteremia
Staphylococcus Aureus
Staphylococcus Aureus Bacteremia
+2 more
COMPLETED
PHASE1/PHASE2
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
NCT01971762
Staphylococcus Aureus Bacteremia
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SAFO trial is a multicentre, superiority, open-label, randomized, phase IV-III, two-armed parallel (1:1) groups clinical trial comparing combination treatment with fosfomycin and cloxacillin with standard therapy with cloxacillin in adult patients with MSSA bacteremia.
Patients will be randomized to:
* Standard treatment group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. If creatinine clearance is \<30 mL/min cloxacillin will be administrated at dose of 2g every 6 hours.
* Combination therapy group: patients will receive intravenous cloxacillin as explained above and fosfomycin 3 g/6h for the duration of 7 days treatment. In case of renal failure, fosfomycin will be administrated as follow:
Creatinine clearance (mL/min) Fosfomycin dosage \>40 3 g every 6 hours 20-40 3 g every 12 hours 10-20 3g every 24 hours \<10 3 g every 48 hours Haemodialysis 3 g after haemodialysis Continuous renal replacement therapy 3 g every 24h hours
The duration of overall antibiotic treatment and the duration of intravenous treatment will be determined according to clinical criteria depending on status (complicated or uncomplicated bacteremia, source of infection) by responsible clinician according with current guidelines. Patient with complicated bacteremia will receive at least 4-6 week of antibiotic treatment.
Primary endpoint
Treatment success at day 7 is a composite outcome defined by all of the following criteria met after randomization:
* Patient alive at day 7 AND
* Clinical improvement measured by stable or improved quick SOFA score (compared with baseline) at day 7 AND
* Fever resolved at day 7 AND
* Negative blood cultures for S. aureus at day 7.
In case of statistical differences observed between groups in the primary endpoint, investigators will perform a hierarchical testing analyzing the treatment success at Test of Cure (TOC visit, 12 weeks after randomization).
Treatment success at TOC visit is defined by presence of all of the following:
* Patient alive at TOC;
* No isolation of MSSA in blood culture or in another sterile site from day 8 until Test of Cure visit (TOC, 12 weeks after randomisation). In case of patients with prolonged course of antibiotic treatment (more than 10 weeks), TOC visit will be performed two weeks after the end of treatment (EOT).
Treatment failure is defined by the presence of one of the following condition: all-cause mortality at TOC, positive blood cultures at day 7 or later, withdraw of the study because of adverse events related to study treatment, requirement of an additional MSSA-active antibiotic until day 7, lacking of clinical improvement at day 7.
Secondary endpoint
Clinical secondary endpoints:
* To compare all-cause mortality at days 7, 14, EOT and 90 after randomization in cloxacillin treatment group versus cloxacillin and fosfomycin treatment group.
* To evaluate persistent bacteremia (at least one positive blood culture) at day 3 and persistent bacteremia at day 7 after randomization in the two arms of treatment.
* To determine the microbiological relapse as defined by at least one positive blood culture for MSSA at least 72 hours after a preceding negative culture in the two arms of treatment.
* To evaluate microbiological treatment failure as defined by positive sterile site culture for MSSA at least 14 days after randomisation in the two arms.
* To determine the number of patients with persistent and relapsing bacteremia in the two arms of treatment.
* To evaluate the number of patients with complicated bacteremia, defined by persistent bacteremia, endocarditis or metastatic emboli, prosthetic devices) in the two arms of treatment.
* To determine the length of stay in intensive care unit and in hospital in both arms of treatment.
* Duration of intravenous antibiotic treatment. Sub group analysis for patients at high risk (persistent bacteraemia, metastatic infection, unknown focus of bacteraemia, endocarditis, pneumonia).
Microbiological secondary endpoints:
* To determine emergency of fosfomycin-resistant strains during therapy in the arm of combination treatment.
* To evaluate operon agr functionality and its relationship with Minimum Inhibitory Concentration (MIC) changes to vancomycin (VAN) and daptomycin (DAP) and with biofilm production.
* To analyze VAN and DAP MIC as markers of complications during bacteraemia.
* To determine the "in vitro" cloxacillin plus fosfomycin combination synergy.
* To realize whole genome sequencing and its changes in patients with treatment failure.
Pharmacological secondary endpoints:
* To determine minimum and maximum concentration in steady state of fosfomycin and cloxacillin.
* To evaluate pharmacokinetic variability of these concentration.
* To study the association between PK parameters and efficacy.
Security secondary endpoints:
To evaluate the security of cloxacillin and fosfomycin combination compared with cloxacillin monotherapy.
Patients will be randomized to:
* Standard treatment group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. If creatinine clearance is \<30 mL/min cloxacillin will be administrated at dose of 2g every 6 hours.
* Combination therapy group: patients will receive intravenous cloxacillin as explained above and fosfomycin 3 g/6h for the duration of 7 days treatment. In case of renal failure, fosfomycin will be administrated as follow:
Creatinine clearance (mL/min) Fosfomycin dosage \>40 3 g every 6 hours 20-40 3 g every 12 hours 10-20 3g every 24 hours \<10 3 g every 48 hours Haemodialysis 3 g after haemodialysis Continuous renal replacement therapy 3 g every 24h hours
The duration of overall antibiotic treatment and the duration of intravenous treatment will be determined according to clinical criteria depending on status (complicated or uncomplicated bacteremia, source of infection) by responsible clinician according with current guidelines. Patient with complicated bacteremia will receive at least 4-6 week of antibiotic treatment.
Primary endpoint
Treatment success at day 7 is a composite outcome defined by all of the following criteria met after randomization:
* Patient alive at day 7 AND
* Clinical improvement measured by stable or improved quick SOFA score (compared with baseline) at day 7 AND
* Fever resolved at day 7 AND
* Negative blood cultures for S. aureus at day 7.
In case of statistical differences observed between groups in the primary endpoint, investigators will perform a hierarchical testing analyzing the treatment success at Test of Cure (TOC visit, 12 weeks after randomization).
Treatment success at TOC visit is defined by presence of all of the following:
* Patient alive at TOC;
* No isolation of MSSA in blood culture or in another sterile site from day 8 until Test of Cure visit (TOC, 12 weeks after randomisation). In case of patients with prolonged course of antibiotic treatment (more than 10 weeks), TOC visit will be performed two weeks after the end of treatment (EOT).
Treatment failure is defined by the presence of one of the following condition: all-cause mortality at TOC, positive blood cultures at day 7 or later, withdraw of the study because of adverse events related to study treatment, requirement of an additional MSSA-active antibiotic until day 7, lacking of clinical improvement at day 7.
Secondary endpoint
Clinical secondary endpoints:
* To compare all-cause mortality at days 7, 14, EOT and 90 after randomization in cloxacillin treatment group versus cloxacillin and fosfomycin treatment group.
* To evaluate persistent bacteremia (at least one positive blood culture) at day 3 and persistent bacteremia at day 7 after randomization in the two arms of treatment.
* To determine the microbiological relapse as defined by at least one positive blood culture for MSSA at least 72 hours after a preceding negative culture in the two arms of treatment.
* To evaluate microbiological treatment failure as defined by positive sterile site culture for MSSA at least 14 days after randomisation in the two arms.
* To determine the number of patients with persistent and relapsing bacteremia in the two arms of treatment.
* To evaluate the number of patients with complicated bacteremia, defined by persistent bacteremia, endocarditis or metastatic emboli, prosthetic devices) in the two arms of treatment.
* To determine the length of stay in intensive care unit and in hospital in both arms of treatment.
* Duration of intravenous antibiotic treatment. Sub group analysis for patients at high risk (persistent bacteraemia, metastatic infection, unknown focus of bacteraemia, endocarditis, pneumonia).
Microbiological secondary endpoints:
* To determine emergency of fosfomycin-resistant strains during therapy in the arm of combination treatment.
* To evaluate operon agr functionality and its relationship with Minimum Inhibitory Concentration (MIC) changes to vancomycin (VAN) and daptomycin (DAP) and with biofilm production.
* To analyze VAN and DAP MIC as markers of complications during bacteraemia.
* To determine the "in vitro" cloxacillin plus fosfomycin combination synergy.
* To realize whole genome sequencing and its changes in patients with treatment failure.
Pharmacological secondary endpoints:
* To determine minimum and maximum concentration in steady state of fosfomycin and cloxacillin.
* To evaluate pharmacokinetic variability of these concentration.
* To study the association between PK parameters and efficacy.
Security secondary endpoints:
To evaluate the security of cloxacillin and fosfomycin combination compared with cloxacillin monotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Methicillin Susceptible Staphylococcus Aureus Septicemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination therapy group
intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
Group Type
EXPERIMENTAL
Combination therapy group
Intervention Type
DRUG
Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Standard therapy group
intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
Group Type
ACTIVE_COMPARATOR
Standard therapy group
Intervention Type
DRUG
Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination therapy group
Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Intervention Type
DRUG
Standard therapy group
Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects, aged ≥ 18 years;
* MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to randomisation in patients with clinical suspicion of infection;
* Written informed consent of the participant or the legal representative.
* MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to randomisation in patients with clinical suspicion of infection;
* Written informed consent of the participant or the legal representative.
Exclusion Criteria
* Severe clinical status with expected death \<48h.
* Severe hepatic cirrhosis (Child-Pugh C).
* Moderate-severe cardiac chronic failure (NYHA III-IV).
* Prosthetic endocarditis (need for concomitant antibiotic therapy active against S. aureus together with the study antibiotics for the first 7 days of the study).
* No pre-existing evidence of S. aureus fosfomycin non-susceptibility.
* Known hypersensitivity to cloxacillin or fosfomycin.
* Polymicrobial bacteraemia with more than one microorganism in blood cultures.
* A positive pregnancy test or pregnancy or lactation at the time of inclusion.
* Miastenia gravis.
* Participation in another clinical trial.
* Previous participation in the present clinical trial.
* Acute SARS-CoV2 infection.
* Severe hepatic cirrhosis (Child-Pugh C).
* Moderate-severe cardiac chronic failure (NYHA III-IV).
* Prosthetic endocarditis (need for concomitant antibiotic therapy active against S. aureus together with the study antibiotics for the first 7 days of the study).
* No pre-existing evidence of S. aureus fosfomycin non-susceptibility.
* Known hypersensitivity to cloxacillin or fosfomycin.
* Polymicrobial bacteraemia with more than one microorganism in blood cultures.
* A positive pregnancy test or pregnancy or lactation at the time of inclusion.
* Miastenia gravis.
* Participation in another clinical trial.
* Previous participation in the present clinical trial.
* Acute SARS-CoV2 infection.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut d'Investigació Biomèdica de Bellvitge
OTHER
Sponsor Role
collaborator
Instituto de Salud Carlos III
OTHER_GOV
Sponsor Role
collaborator
Miquel Pujol
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Miquel Pujol
Principal Investigator, Medical Doctor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Miquel Pujol Rojo, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitari Bellvitge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Site Status
Hospital Sant Joan Despí Moisés Broggi
Sant Joan Despí, Barcelona, Spain
Site Status
University Hospital Cruces
Barakaldo, , Spain
Site Status
Bellvitge University Hospital
Barcelona, , Spain
Site Status
Hospital del Mar
Barcelona, , Spain
Site Status
University Hospital Clínic de Barcelona
Barcelona, , Spain
Site Status
University Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
University Hospital Arnau de Vilanova
Lleida, , Spain
Site Status
University Hospital Lucus Agustí
Lugo, , Spain
Site Status
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Site Status
University Hospital 12 de Octubre
Madrid, , Spain
Site Status
University Hospital Sant Joan
Reus, , Spain
Site Status
Corporació Sanitària Parc Taulí
Sabadell, , Spain
Site Status
University Hospital Virgen Macarena
Seville, , Spain
Site Status
University Hospital Joan XXIII
Tarragona, , Spain
Site Status
University Hospital Mùtua de Terrassa
Terrassa, , Spain
Site Status
Hospital Clínico Lozano Blesa
Zaragoza, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Bergin SP, Holland TL, Fowler VG Jr, Tong SYC. Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus. Curr Top Microbiol Immunol. 2017;409:263-296. doi: 10.1007/82_2015_5001.
Reference Type
BACKGROUND
van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11.
Reference Type
BACKGROUND
Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MA, Benito N, Rodriguez-Bano J, Espejo E, Pujol M; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013 Nov;19(11):1049-57. doi: 10.1111/1469-0691.12108. Epub 2013 Jan 17.
Reference Type
BACKGROUND
Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, Nieberg P, Spellberg B, Wong-Beringer A. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis. 2020 Feb 3;70(4):566-573. doi: 10.1093/cid/ciz257.
Reference Type
BACKGROUND
Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Dominguez MA, Gasch O, Lora-Tamayo J, Miro JM, Palomar M, Pascual A, Pericas JM, Pujol M, Rodriguez-Bano J, Shaw E, Soriano A, Valles J. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015 Nov;33(9):625.e1-625.e23. doi: 10.1016/j.eimc.2015.03.015. Epub 2015 May 1.
Reference Type
BACKGROUND
Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Torok ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG). Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14.
Reference Type
BACKGROUND
Grillo S, Cuervo G, Carratala J, Grau I, Pallares N, Tebe C, Guillem Tio L, Murillo O, Ardanuy C, Dominguez MA, Shaw E, Gudiol C, Pujol M. Impact of beta-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019 Oct 15;69(9):1480-1488. doi: 10.1093/cid/ciz018.
Reference Type
BACKGROUND
Grabein B, Graninger W, Rodriguez Bano J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017 Jun;23(6):363-372. doi: 10.1016/j.cmi.2016.12.005. Epub 2016 Dec 9.
Reference Type
BACKGROUND
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
Reference Type
BACKGROUND
Grillo S, Pujol M, Miro JM, Lopez-Contreras J, Euba G, Gasch O, Boix-Palop L, Garcia-Pais MJ, Perez-Rodriguez MT, Gomez-Zorrilla S, Oriol I, Lopez-Cortes LE, Pedro-Botet ML, San-Juan R, Aguado JM, Gioia F, Iftimie S, Morata L, Jover-Saenz A, Garcia-Pardo G, Loeches B, Izquierdo-Cardenas A, Goikoetxea AJ, Gomila-Grange A, Dietl B, Berbel D, Videla S, Hereu P, Padulles A, Pallares N, Tebe C, Cuervo G, Carratala J; SAFO study group. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023 Oct;29(10):2518-2525. doi: 10.1038/s41591-023-02569-0. Epub 2023 Oct 2.
Reference Type
DERIVED
Grillo S, Cuervo G, Carratala J, San-Juan R, Aguado JM, Morata L, Gomez-Zorrilla S, Lopez-Contreras J, Gasch O, Gomila-Grange A, Iftimie S, Garcia-Pardo G, Calbo E, Boix-Palop L, Oriol I, Jover-Saenz A, Lopez-Cortes LE, Euba G, Aguirregabiria M, Garcia-Pais MJ, Gioia F, Pano JR, Pedro-Botet ML, Benitez RM, Perez-Rodriguez MT, Meije Y, Loeches-Yague MB, Horna G, Berbel D, Dominguez MA, Padulles A, Cobo S, Hereu P, Videla S, Tebe C, Pallares N, Miro JM, Pujol M; SAFO study group and the Spanish Network for Research in Infectious Diseases (REIPI). Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial. BMJ Open. 2021 Aug 5;11(8):e051208. doi: 10.1136/bmjopen-2021-051208.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-001207-37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis
NCT05664568
UNKNOWN
PHASE2
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
NCT00729937
COMPLETED
PHASE2/PHASE3
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia
NCT06574399
RECRUITING
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
NCT00548002
COMPLETED
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
NCT05382312
COMPLETED
PHASE2
Staphylococcus Aureus Bacteraemia in Adults
NCT02098850
UNKNOWN
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
NCT02282605
COMPLETED
PHASE1/PHASE2
Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
NCT01589185
COMPLETED
PHASE1/PHASE2
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
NCT04503252
COMPLETED
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
NCT02284555
COMPLETED
PHASE4
Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients
NCT01489878
COMPLETED
Retapamulin as a Decolonizing Agent for MRSA
NCT03304873
COMPLETED
PHASE3
Penicillin Against Flucloxacillin Treatment Evaluation
NCT03632642
WITHDRAWN
PHASE4
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
NCT01619410
TERMINATED
NA
Linezolid Plus Standard of Care
NCT06958835
RECRUITING
NA
Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus
NCT01211470
COMPLETED
PHASE2
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
NCT00463801
TERMINATED
PHASE4
Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
NCT00997139
COMPLETED
NA
Aurograb and Vancomycin in MRSA Infection
NCT00217841
COMPLETED
PHASE3
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
NCT05225558
TERMINATED
PHASE2
Recurrent S. Aureus Infections in Osteoarticular Infections
NCT04712123
UNKNOWN
Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery
NCT02595112
COMPLETED
NA
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
NCT00622882
UNKNOWN
NA
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
NCT06004037
ACTIVE_NOT_RECRUITING
PHASE2